Clewell Harvey J, Gentry P Robinan, Kester Janet E, Andersen Melvin E
ENVIRON Health Sciences Institute, Ruston, Louisiana, USA.
Crit Rev Toxicol. 2005 Jun;35(5):413-33. doi: 10.1080/10408440590931994.
One of the more problematic aspects of the application of physiologically based pharmacokinetic (PBPK) models in risk assessment is the question of whether the model has been adequately validated to provide confidence in the dose metrics calculated with it. A number of PBPK models have been developed for perchloroethylene (PCE), differing primarily in the parameters estimated for metabolism. All of the models provide reasonably accurate simulations of selected kinetic data for PCE in mice and humans and could thus be considered to be "validated" to some extent. However, quantitative estimates of PCE cancer risk are critically dependent on the prediction of the rate of metabolism at low environmental exposures. Recent data on the urinary excretion of trichloroacetic acid (TCA), the major metabolite of PCE, for human subjects exposed to lower concentrations than those used in previous studies, make it possible to compare the high- to low-dose extrapolation capability of the various published human models. The model of Gearhart et al., which is the only model to include a description of TCA kinetics, provided the closest predictions of the urinary excretion observed in these low-concentration exposures. Other models overestimated metabolite excretion in this study by 5- to 15-fold. A systematic discrepancy between model predictions and experimental data for the time course of the urinary excretion of TCA suggested a contribution from TCA formed by metabolism of PCE in the kidney and excreted directly into the urine. A modification of the model of Gearhart et al. to include metabolism of PCE to TCA in the kidney at 10% of the capacity of the liver, with direct excretion of the TCA formed in the kidney into the urine, markedly improved agreement with the experimental time-course data, without altering predictions of liver metabolism. This case study with PCE demonstrates the danger of relying on parent chemical kinetic data to validate a model that will be used for the prediction of metabolism.
基于生理学的药代动力学(PBPK)模型在风险评估中的应用,存在一个较为棘手的问题,即该模型是否经过充分验证,从而让人对其计算出的剂量指标有信心。针对全氯乙烯(PCE)已开发出多个PBPK模型,主要区别在于代谢相关参数的估计。所有模型对小鼠和人类PCE的选定动力学数据都能提供较为准确的模拟,因此在某种程度上可被视为“经过验证”。然而,PCE癌症风险的定量估计严重依赖于低环境暴露下代谢速率的预测。近期有关三氯乙酸(TCA)尿排泄的数据,TCA是PCE的主要代谢产物,这些数据来自暴露于比先前研究中更低浓度的人类受试者,这使得比较各种已发表的人类模型的高剂量到低剂量外推能力成为可能。Gearhart等人的模型是唯一包含TCA动力学描述的模型,它对这些低浓度暴露中观察到的尿排泄提供了最接近的预测。在本研究中,其他模型将代谢物排泄高估了5至15倍。TCA尿排泄时间进程的模型预测与实验数据之间的系统性差异表明,肾脏中PCE代谢形成并直接排泄到尿液中的TCA起到了一定作用。对Gearhart等人的模型进行修改,使其包括肾脏中PCE以肝脏代谢能力10%的速率代谢为TCA,并将肾脏中形成的TCA直接排泄到尿液中,这显著改善了与实验时间进程数据的一致性,同时不改变肝脏代谢的预测。这个关于PCE的案例研究表明,依靠母体化学动力学数据来验证一个将用于预测代谢的模型存在风险。